Dendritic cells (DCs) are well known for their capacity to induce adaptive antitumor immune response through Ag presentation and tumor-specific T cell activation. Recent findings reveal that besides this role, DCs may display additional antitumor effects. In this study, we provide evidence that LPS- or IFN-γ-activated rat bone marrow-derived dendritic cells (BMDCs) display killing properties against tumor cells. These cytotoxic BMDCs exhibit a mature DC phenotype, produce high amounts of IL-12, IL-6, and TNF-α, and retain their phagocytic properties. BMDC-mediated tumor cell killing requires cell-cell contact and depends on NO production, but not on perforin/granzyme or on death receptors. Furthermore, dead tumor cells do not exhibit characteristics of apoptosis. Thus, intratumoral LPS injections induce an increase of inducible NO synthase expression in tumor-infiltrating DCs associated with a significant arrest of tumor growth. Altogether, these results suggest that LPS-activated BMDCs represent powerful tumoricidal cells which enforce their potential as anticancer cellular vaccines.
CITATION STYLE
Nicolas, A., Cathelin, D., Larmonier, N., Fraszczak, J., Puig, P.-E., Bouchot, A., … Bonnotte, B. (2007). Dendritic Cells Trigger Tumor Cell Death by a Nitric Oxide-Dependent Mechanism. The Journal of Immunology, 179(2), 812–818. https://doi.org/10.4049/jimmunol.179.2.812
Mendeley helps you to discover research relevant for your work.